全球非侵入性癌症診斷市場

預計到 2030 年全球非侵入性癌症診斷市場規模將達 2,243 億美元

全球非侵入性癌症診斷市場規模預計在2024年為1564億美元，預計到2030年將達到2243億美元，在2024-2030年的分析期內，複合年成長率為6.2%。免疫化學是本報告分析的細分領域之一，預計其複合年成長率為8.1%，到分析期結束時規模將達到1005億美元。臨床微生物學細分領域在分析期間的複合年成長率預計為4.0%。

美國市場規模估計為 426 億美元，中國市場預計複合年成長率為 10.1%

美國非侵入性癌症診斷市場規模預計在2024年達到426億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到468億美元，在2024-2030年的分析期間內，複合年成長率為10.1%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為2.9%和6.2%。在歐洲，預計德國市場的複合年成長率為4.1%。

全球非侵入性癌症診斷市場—主要趨勢和促進因素摘要

我們能否在不使用手術刀或切片穿刺針的情況下徹底改變癌症檢測？

非侵入性癌症診斷技術正在改變腫瘤學格局，它能夠透過體液和影像學檢查（而非侵入性組織切片檢查）實現惡性腫瘤的早期、精準檢測和監測。這些技術利用血液、尿液、唾液和呼出氣體中的生物標記物，使臨床醫生能夠在早期階段識別癌症，從而改善預後並降低手術風險。液態切片、循環腫瘤DNA (ctDNA) 分析、外泌體分析和分子成像等技術正在成為個人化腫瘤治療的重要工具。這些方法將在篩檢癌、卵巢和肺癌等難以取得的癌症方面發揮特別重要的作用，因為傳統的切片檢查在這些癌症中產量比率高、獲益低。

基因組學、蛋白質組學和先進成像技術的融合，將非侵入性診斷的範圍從簡單的檢測拓展到腫瘤分型、突變分析和即時療效監測。例如，液態切片不僅用於早期癌症診斷，還用於在治療期間識別抗藥性突變，並追蹤治療後的微量殘存疾病。這些方法具有重複檢測、減輕患者不適和快速治療的優勢，符合以患者為中心的精準癌症治療趨勢。這些方法正擴大被納入全球領先腫瘤中心的臨床指南和研究設計中。

為什麼全球對非侵入性快速診斷的需求日益增加？

受人口、臨床和經濟等多種因素的影響，對非侵入性診斷的需求正在激增。全球癌症發病率上升、人口老化以及人們對早期發現益處的認知不斷提高，這些因素正在推動醫療保健系統實施擴充性、無創傷且經濟高效的篩檢工具。各國政府和公共衛生計畫正在優先考慮非侵入性診斷，以擴大基於人群的篩檢，尤其是在切片檢查設施有限的中低收入國家。這些工具提供了在症狀出現之前進行早期療育的可能性，從而減輕晚期癌症治療的負擔並提高存活率。

在高所得國家，向基於價值的醫療模式的轉變正迫使支付方和醫療服務提供者支持旨在減少不必要程序、住院和延誤治療的診斷解決方案。非侵入性檢測能夠有效地進行風險分層，並減少對高成本影像檢查和探查性手術的依賴。此外，患者偏好也日益影響臨床選擇。微創治療方案在那些不願忍受疼痛、併發症和反覆侵入性監測的患者族群中越來越受歡迎。從肺癌的呼吸分析到大腸直腸癌的糞便DNA檢測，各種平台正逐漸受到尋求便捷居家診斷解決方案的患者的青睞。

最尖端科技如何提高診斷的準確性和可近性？

次世代定序(NGS)、數位 PCR、微流體和機器學習等新興技術正在提高非侵入性癌症診斷的敏感度、特異性和擴充性。基於 NGS 的液態切片如今只需 1 毫升血漿即可檢測單核苷酸變異、拷貝數變異和融合基因，從而實現全面的腫瘤分析。數位 PCR 平台可對 ctDNA 進行超靈敏定量分析，並以無與倫比的精度支援長期監測。微流體晶片已被開發用於即時分離循環性腫瘤細胞(CTC) 和外泌體，支援分散式檢查和照護現場診斷。

人工智慧 (AI) 和數據分析正應用於放射組學和病理成像，以從非侵入性掃描中提取深層表現型特徵。放射基因組學能夠整合影像生物標記和基因組數據，從而非侵入性地推斷腫瘤的分子亞型。雲端連接診斷平台使臨床醫生能夠透過連續血液檢測和影像掃描遠端監測病情進展和治療反應。新興企業和醫療科技創新者正專注於多重檢測、穿戴式感測器和家用診斷套件，以實現普及化，並實現對高風險族群的主動癌症監測。

推動非侵入性癌症診斷市場快速成長的因素是什麼？

非侵入性癌症診斷市場的成長受到幾股重塑全球腫瘤生態系統的強大力量的推動。其中一個關鍵促進因素是精準醫療的日益普及，其中早期非侵入性檢測是治療計劃、伴隨診斷和即時監測的基石。生物製藥公司擴大與診斷公司合作，共同開發用於指南標靶治療選擇和臨床試驗入組的檢測方法，從而加速商業化並獲得報銷支持。

液態切片和非侵入性檢測獲得監管機構、臨床協會和付款方的認可也是關鍵的成長動力。美國食品藥物管理局 (FDA) 早期核准了基於 ctDNA 的伴隨診斷產品，美國醫療保險和醫療補助服務中心 (CMS) 也對多項癌症檢測測試做出了有利的報銷決定，這些舉措檢驗了市場潛力並刺激了投資。臨床試驗和真實世界研究持續證明這些工具在檢測早期癌症、追蹤抗藥性突變和改善治療效果的效用。同時，創業投資的流入和併購活性化正在推動技術創新和全球市場的擴張。

多組體學平台、人工智慧增強診斷和分散式樣本收集的日益普及也降低了成本門檻，將非侵入性癌症診斷帶入門診、基層醫療診所，甚至患者家中。隨著癌症治療逐漸轉向以預防、監測和生存為重點的持續護理模式，非侵入性診斷將在將癌症從末期疾病轉變為可控的慢性疾病方面發揮核心作用。憑藉強大的研發開發平臺、有利的政策環境和強勁的臨床發展勢頭，癌症市場預計將在各個適應症和地區實現指數級成長。

部分

產品類型（免疫化學、臨床微生物學、就地檢驗、血液學、其他產品類型）、癌症類型（肺癌、乳癌、固體癌、血癌、卵巢癌、其他癌症類型）、最終用戶（醫院和診所、診斷中心、門診診所、其他最終用戶）

受訪公司範例（值得關注的34家公司）

• Biocept, Inc.
• Caris Life Sciences
• Datar Cancer Genetics
• DELFI Diagnostics
• Exact Sciences Corporation
• Foundation Medicine
• Freenome Holdings, Inc.
• Guardant Health, Inc.
• iCAD, Inc.
• Illumina, Inc.
• Lucence Health Inc.
• Myriad Genetics, Inc.
• Natera, Inc.
• Oncocyte Corporation
• Pacific Edge Ltd.
• QIAGEN NV
• Roche Diagnostics
• SAGA Diagnostics AB
• Thermo Fisher Scientific
• Veracyte, Inc.

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口（成品和原始OEM）來預測其競爭地位的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

全球產業分析師密切關注來自全球頂尖首席經濟學家（14,949位）、智庫（62家）以及貿易和產業協會（171家）的專家的意見，以評估其對生態系統的影響並應對新的市場現實。我們追蹤了來自每個主要國家的專家和經濟學家對關稅及其對本國影響的看法。

全球產業分析師預計，這場動盪將在未來2-3個月內逐漸平息，新的世界秩序將更加清晰地建立。全球產業分析師正在即時追蹤這些事態發展。

2025年4月：談判階段

在4月的報告中，我們將探討關稅對全球整體市場的影響，並提供區域市場調整。我們的預測是基於歷史數據和不斷變化的市場影響因素。

2025年7月：最終關稅調整

在各國宣布最終重置後，客戶將在 7 月收到免費更新，最終更新將包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤了 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業以及各領域專家的最具影響力的首席經濟學家，他們共用了這場前所未有的全球經濟狀況模式轉移的影響。我們超過 16,491 份報告大多遵循基於里程碑的兩階段發布計劃。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 競賽

Global Non-Invasive Cancer Diagnostics Market to Reach US$224.3 Billion by 2030

The global market for Non-Invasive Cancer Diagnostics estimated at US$156.4 Billion in the year 2024, is expected to reach US$224.3 Billion by 2030, growing at a CAGR of 6.2% over the analysis period 2024-2030. Immunochemistry, one of the segments analyzed in the report, is expected to record a 8.1% CAGR and reach US$100.5 Billion by the end of the analysis period. Growth in the Clinical Microbiology segment is estimated at 4.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$42.6 Billion While China is Forecast to Grow at 10.1% CAGR

The Non-Invasive Cancer Diagnostics market in the U.S. is estimated at US$42.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$46.8 Billion by the year 2030 trailing a CAGR of 10.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.9% and 6.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Non-Invasive Cancer Diagnostics Market - Key Trends & Drivers Summarized

Can Cancer Detection Be Revolutionized Without a Scalpel or Biopsy Needle?

Non-invasive cancer diagnostics are transforming the oncology landscape by enabling early, accurate detection and monitoring of malignancies through bodily fluids and imaging, rather than invasive tissue biopsies. Leveraging biomarkers found in blood, urine, saliva, and exhaled breath, these technologies allow clinicians to identify cancers at nascent stages, improving prognosis and reducing procedural risks. Techniques such as liquid biopsies, circulating tumor DNA (ctDNA) analysis, exosome profiling, and molecular imaging are emerging as critical tools in personalized oncology. These approaches are especially impactful in screening hard-to-access cancers like pancreatic, ovarian, and lung, where traditional biopsies pose high risk and low yield.

The convergence of genomics, proteomics, and advanced imaging has expanded the scope of non-invasive diagnostics beyond mere detection to encompass tumor typing, mutation profiling, and real-time treatment response monitoring. Liquid biopsies, for instance, are being used not only for initial cancer diagnosis but also for identifying resistance mutations during therapy and tracking minimal residual disease post-treatment. These modalities offer advantages in repeat testing, reduced patient discomfort, and faster turnaround, aligning with the growing emphasis on patient-centric and precision-based cancer care. They are increasingly being integrated into clinical guidelines and trial designs across major oncology centers worldwide.

Why Is the Demand for Less Invasive, Faster Diagnostics Gaining Ground Globally?

The demand for non-invasive diagnostics is surging due to a combination of demographic, clinical, and economic factors. Globally rising cancer incidence, aging populations, and growing awareness of the benefits of early detection are prompting health systems to adopt screening tools that are scalable, non-traumatic, and cost-effective. Governments and public health programs are prioritizing non-invasive diagnostics to expand population-based screening, especially in low- and middle-income countries where access to surgical biopsy facilities remains limited. These tools offer the possibility of early intervention before symptom onset, thereby reducing the burden of late-stage cancer treatment and improving survival rates.

In high-income countries, the shift toward value-based care models is compelling payers and providers to favor diagnostic solutions that reduce unnecessary procedures, hospitalizations, and treatment delays. Non-invasive tests enable efficient risk stratification and reduce the dependence on high-cost imaging or exploratory surgery. Furthermore, patient preference is increasingly influencing clinical choices-minimally invasive options are gaining traction among individuals wary of pain, complications, and repeated invasive monitoring. From lung cancer breath analysis to stool-DNA testing for colorectal cancer, diverse platforms are being embraced by patients seeking accessible, home-based diagnostic solutions.

How Are Cutting-Edge Technologies Elevating Diagnostic Precision and Accessibility?

Advanced technologies such as next-generation sequencing (NGS), digital PCR, microfluidics, and machine learning are enhancing the sensitivity, specificity, and scalability of non-invasive cancer diagnostics. NGS-based liquid biopsies now detect single nucleotide variants, copy number alterations, and fusion genes from as little as 1 mL of plasma, enabling comprehensive tumor profiling. Digital PCR platforms offer ultra-sensitive quantification of ctDNA, supporting longitudinal monitoring with unmatched precision. Microfluidic chips are being developed to isolate circulating tumor cells (CTCs) and exosomes in real time, supporting decentralized testing and point-of-care diagnostics.

Artificial intelligence (AI) and data analytics are being applied to radiomics and pathology imaging to extract deep phenotypic features from non-invasive scans. Radiogenomics is enabling the integration of imaging biomarkers with genomic data to non-invasively infer molecular subtypes of tumors. Cloud-connected diagnostic platforms allow clinicians to remotely monitor disease progression and therapy response using serial blood tests or imaging scans. Startups and medtech innovators are focusing on multiplexed assays, wearable sensors, and at-home diagnostic kits, democratizing access and enabling proactive cancer surveillance for high-risk populations.

What’s Driving the Breakneck Growth in the Non-Invasive Cancer Diagnostics Market?

The growth in the non-invasive cancer diagnostics market is driven by several powerful forces that are reshaping the global oncology ecosystem. A key driver is the growing adoption of precision medicine, where early, non-invasive detection is foundational to treatment planning, companion diagnostics, and real-time monitoring. Biopharma companies are increasingly collaborating with diagnostic firms to co-develop assays that guide targeted therapy selection and clinical trial enrollment, accelerating commercialization and reimbursement support.

Another crucial growth catalyst is the rising acceptance of liquid biopsies and non-invasive tests by regulatory bodies, clinical societies, and payers. The FDA’s accelerated approvals of ctDNA-based companion diagnostics and CMS’s favorable reimbursement decisions for multi-cancer detection tests have validated market potential and driven investment. Clinical trials and real-world studies continue to demonstrate the utility of these tools in detecting early-stage cancers, tracking resistance mutations, and improving treatment outcomes. In parallel, rising venture capital inflows and M&A activity are fueling innovation and global market expansion.

The expanding use of multi-omics platforms, AI-enhanced diagnostics, and decentralized sample collection is also reducing cost barriers and bringing non-invasive cancer diagnostics to outpatient settings, primary care clinics, and even patients’ homes. As oncology transitions into a continuous-care model focused on prevention, monitoring, and survivorship, non-invasive diagnostics will play a central role in transforming cancer from a late-stage crisis to a manageable chronic condition. With robust R&D pipelines, supportive policy landscapes, and strong clinical momentum, the market is poised for exponential growth across indications and geographies.

SCOPE OF STUDY:

The report analyzes the Non-Invasive Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology, Other Product Types); Cancer Type (Lung Cancer, Breast Cancer, Solid Tumors, Blood Cancer, Ovarian Cancer, Other Cancer Types); End-Use (Hospitals & Clinics, Diagnostic Centers, Ambulatory Care, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Biocept, Inc.
• Caris Life Sciences
• Datar Cancer Genetics
• DELFI Diagnostics
• Exact Sciences Corporation
• Foundation Medicine
• Freenome Holdings, Inc.
• Guardant Health, Inc.
• iCAD, Inc.
• Illumina, Inc.
• Lucence Health Inc.
• Myriad Genetics, Inc.
• Natera, Inc.
• Oncocyte Corporation
• Pacific Edge Ltd.
• QIAGEN N.V.
• Roche Diagnostics
• SAGA Diagnostics AB
• Thermo Fisher Scientific
• Veracyte, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Non-Invasive Cancer Diagnostics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Surge in Early Detection Initiatives and Screening Programs Drives Demand for Non-Invasive Cancer Diagnostics
  • Growing Preference for Liquid Biopsy Over Surgical Procedures Strengthens Market for Blood-Based Diagnostics
  • Advancements in cfDNA, ctDNA, and Exosome Analysis Propel Precision Oncology Adoption
  • Expansion of Multicancer Detection Panels Throws the Spotlight on Pan-Cancer Non-Invasive Testing Platforms
  • Rising Focus on Monitoring Minimal Residual Disease (MRD) Sustains Use in Post-Treatment Surveillance
  • Integration With AI-Powered Biomarker Analysis Enhances Predictive Accuracy and Risk Stratification
  • Increased Use in Companion Diagnostics Supports Targeted Therapy Matching for Personalized Cancer Care
  • OEM Partnerships With Pharma and Diagnostic Labs Accelerate Co-Development of Stratified Screening Solutions
  • Regulatory Approvals for Non-Invasive Assays Support Clinical Expansion in Lung, Breast, and Colorectal Cancer
  • Emergence of Home-Based Sample Collection Kits Expands Access and Convenience for High-Risk Populations
  • Investment in Cancer Moonshot and Global Screening Programs Drives Research Funding for Non-Invasive Tools
  • Challenges in Sensitivity and Specificity of Early-Stage Detection Propel Innovation in Signal Amplification Techniques
  • Expansion of Reimbursement Frameworks in High-Income Countries Enhances Patient Access to Advanced Testing
  • Use of Urine, Saliva, and Breath Biomarkers Expands Sample Collection Modalities
  • Rising Incidence of Cancer in Aging Populations Supports Demand for Less Invasive Monitoring Methods
  • Technological Advancements in NGS and PCR-Based Platforms Reduce Turnaround Time and Cost Per Test
  • Focus on Longitudinal Disease Tracking and Recurrence Prediction Enhances Market for Serial Testing Solutions
  • Emergence of Wearable Biosensor Technologies Opens Future Pathways for Continuous Cancer Monitoring
  • Data Integration With EHR and Oncology Informatics Platforms Supports Clinical Decision-Making
  • OEM Strategies to Expand in Emerging Markets Strengthen Geographic Penetration of Non-Invasive Diagnostics
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Non-Invasive Cancer Diagnostics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Immunochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Immunochemistry by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Immunochemistry by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Clinical Microbiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Clinical Microbiology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Clinical Microbiology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Point of Care Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Point of Care Test by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Point of Care Test by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Ovarian Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Ovarian Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Solid Tumors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Solid Tumors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Ambulatory Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Ambulatory Care by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Ambulatory Care by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• JAPAN
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• CHINA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• EUROPE
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• FRANCE
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 98: France Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• GERMANY
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 125: UK Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• INDIA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 182: India Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Non-Invasive Cancer Diagnostics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030
• AFRICA
  • Non-Invasive Cancer Diagnostics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Non-Invasive Cancer Diagnostics by Product Type - Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Non-Invasive Cancer Diagnostics by Product Type - Percentage Breakdown of Value Sales for Immunochemistry, Clinical Microbiology, Point of Care Test, Hematology and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Non-Invasive Cancer Diagnostics by Cancer Type - Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Non-Invasive Cancer Diagnostics by Cancer Type - Percentage Breakdown of Value Sales for Ovarian Cancer, Other Cancer Types, Lung Cancer, Breast Cancer, Solid Tumors and Blood Cancer for the Years 2015, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Non-Invasive Cancer Diagnostics by End-Use - Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Non-Invasive Cancer Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics, Diagnostic Centers, Ambulatory Care and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION